20.66

3.59% -0.77

Pre-market: 20.65 -0.01 -0.05%

Viridian Therapeutics Inc (VRDN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Viridian Therapeutics Inc stock is traded at $20.66, with a volume of 2.21M. It is down -3.59% in the last 24 hours and down -13.99% over the past month. Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Previous Close:

$21.43

Open:

$21.1

24h Volume:

2.21M

Relative Volume:

1.16

Market Cap:

$2.34B

Revenue:

$70.92M

Net Income/Loss:

$-342.21M

P/E Ratio:

-5.4883

EPS:

-3.7644

Net Cash Flow:

$-304.30M

1W Performance:

-5.79%

1M Performance:

-13.99%

6M Performance:

-24.02%

1Y Performance:

+5.95%

1-Day Range:

$20.22

$21.25

1-Week Range:

$20.22

$22.40

52-Week Range:

$13.18

$34.29

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Name

Viridian Therapeutics Inc

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

617.272.4600

Address

221 CRESCENT STREET, WALTHAM

Employee

252

Twitter

Next Earnings Date

2026-11-04

Latest SEC Filings

VRDN's Discussions on Twitter

Compare VRDN vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRDN Viridian Therapeutics Inc	20.66	2.34B	70.92M	-342.21M	-304.30M	-3.7644
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-25	Reiterated	Wedbush	Outperform
Dec-03-25	Initiated	William Blair	Outperform
Nov-24-25	Initiated	Truist	Buy
Aug-25-25	Resumed	Jefferies	Buy
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-25-24	Initiated	TD Cowen	Buy
Sep-11-24	Reiterated	Needham	Buy
Jun-11-24	Initiated	Wolfe Research	Outperform
Jun-06-24	Initiated	Goldman	Buy
May-09-24	Downgrade	B. Riley Securities	Buy → Neutral
May-09-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jun-14-23	Initiated	BTIG Research	Buy
Jun-14-23	Resumed	Credit Suisse	Outperform
May-30-23	Initiated	RBC Capital Mkts	Outperform
Apr-17-23	Initiated	Wells Fargo	Overweight
Mar-30-23	Initiated	Stifel	Buy
Dec-19-22	Initiated	Cowen	Outperform
Dec-19-22	Initiated	Needham	Buy
Dec-16-22	Initiated	Credit Suisse	Outperform
Dec-01-22	Initiated	H.C. Wainwright	Buy
Jun-23-22	Initiated	B. Riley Securities	Buy
Nov-18-21	Initiated	SVB Leerink	Outperform
Oct-12-21	Initiated	Evercore ISI	Outperform
Jan-25-21	Initiated	Ladenburg Thalmann	Buy

View All

Viridian Therapeutics Inc Stock (VRDN) Latest News

Sep 24, 2026

(VRDN) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com

Sep 24, 2026

Sep 22, 2026

Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says - finance.yahoo.com

Sep 22, 2026

RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $38 - Moomoo

Sep 22, 2026

RBC Capital maintains Outperform rating on Viridian Therapeutics, $38 price target - TradingView

Sep 22, 2026

Sep 19, 2026

VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval - Stocktwits

Sep 19, 2026

Sep 17, 2026

Viridian Therapeutics shifts focus to launch ex... - Pluang

Sep 17, 2026

Viridian Therapeutics: Two Products, One Commercial Buildout (NASDAQ:VRDN) - Seeking Alpha

Sep 17, 2026

Sep 08, 2026

Viridian at Wells Fargo conference: launch gains and pipeline build By Investing.com - Investing.com Canada

Sep 08, 2026

Sep 03, 2026

Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying - Benzinga

Sep 03, 2026

Sep 02, 2026

Wells Fargo Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX) - theglobeandmail.com

Sep 02, 2026

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance

Sep 02, 2026

Aug 31, 2026